CXCL12 and pulmonary arterial hypertension: LIT-927 is the first locally and orally active CXCL12 chemokine-neutralizing molecule (neutraligand) shown to display anti-inflammatory effects in vivo, demonstrated in two murine models mimicking allergic airway hypereosinophilia (Regenass et al., 2018) and pulmonary arterial hypertension (Bordenave et al., 2020), respectively.